Xuanhan Hu

Dr. Xuanhan Hu

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Investigative and Clinical Urology
Verified
Journal Article
Open access
PDF file
HWHai-Bin Wei
Hai-Bin Wei
BGBing-Yi Guo
Bing-Yi Guo
YTYao-Fen Tu
Yao-Fen Tu
XHXuanhan Hu
Xuanhan Hu
WZWei Zheng
Wei Zheng
JZJian ZHUO
Jian ZHUO
Wei HB, et al. Investig Clin Urol. 2022 May;63(3):262-272. https://doi.org/10.4111/icu.20210281

21 October 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
XHXuanhan Hu
Xuanhan Hu
JMJia Miao
Jia Miao
JHJiaqing Huang
Jiaqing Huang
LQLin Qian
Lin Qian
DZDahong Zhang
Dahong Zhang
CYChong Yu
Chong Yu
Few studies have focused on the link between active surveillance (AS) and Gleason score upgrade (GSU) and its impact on the prognosis of patients with prostate cancer (PCa). This study aimed to analyze the effect of AS duration on GSU and prognostic value based on risk stratification. All eligible patients were risk-stratified according to AUA guidelines into low-risk (LR), favorable intermediate-risk (FIR), and unfavorable intermediate-risk (UIR) PCa. Within the Surveillance, Epidemiology, and End Results Program (SEER) database, 28,368 LR, 27,243 FIR, and 12,210 UIR PCa patients were included. The relationship between AS duration and GSU was identified with univariate and multivariate logistic regression. Discrimination according to risk stratification of AS duration and GSU was tested by Kaplan–Meier analysis and competing risk regression models. The proportion of patients who chose AS was the highest among LR PCa (3434, 12.1%), while the proportion in UIR PCa was the lowest (887, 7.3%). The AS duration was only associated with GSU in LR PCa, with a high Gleason score (GS) at diagnosis being a strong predictor of GSU for FIR and UIR PCa. Kaplan–Meier analysis indicated that long-term surveillance only made a significant difference in prognosis in UIR PCa. The competing risk analysis indicated that once GS was upgraded to 8 or above, the prognosis in each group was significantly worse. AS is recommended for LR and FIR PCa until GS is upgraded to 8, but AS may not be suitable for some UIR PCa patients.